Sana Biotechnology, Inc. SANA
Sana Biotechnology, Inc. (Nasdaq: SANA) is an endocrine/women's health drug developer. Its lead program, SC451, is in Pre-clinical for Type 1 diabetes. Its next catalyst on record is SC451: IND filing and Phase 1/2 trial initiation (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SC451 — IND filing and Phase 1/2 trial initiation (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SC451 | Type 1 diabetes | cell therapy | Pre-clinical |
| SG293 | Non-Hodgkin lymphoma / B-cell malignancies / B-cell mediated autoimmune diseases | gene therapy | Pre-clinical |
| SG227 | Multiple myeloma | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.